Literature DB >> 17285316

Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib.

Alex Hemeryck1, Rita Geerts, Johan Monbaliu, Stephan Hassler, Tom Verhaeghe, Luc Diels, Willy Verluyten, Ludy van Beijsterveldt, Rao N V S Mamidi, Cor Janssen, Roland De Coster.   

Abstract

PURPOSE: The body distribution of total radioactivity (TR) and bortezomib was investigated in male Sprague-Dawley rats after single and repeated i.v. (bolus) administration with (14)C-labelled bortezomib (VELCADE) (0.2 mg/kg; 0.28 MBq./kg).
METHODS: Bortezomib was dosed on days 1, 4, 8, and 11 (i.e. a clinical dosing cycle) and the animals were sacrificed at selected time points following single and repeated dose administration for the quantification of TR in blood, plasma, and various tissues by liquid scintillation counting following organ dissection or by quantitative whole body autoradiography. In selected tissues, bortezomib levels were determined by LC-MS/MS.
RESULTS: In general, plasma TR levels were less than 10% of the corresponding blood concentrations. TR was rapidly and widely distributed to the tissues with only limited penetration into the central nervous system (CNS). In the tissues, highest levels of TR were measured in bortezomib-eliminating organs (liver and kidney), lymphoid tissues, and regions of rapidly dividing cells (e.g. the bone marrow, intestinal mucosa). Low TR concentrations were found in the CNS (tissue-to-blood ratio of approximately 0.05 after repeated dosing). With the exception of the liver, TR consisted almost exclusively of the parent drug. Tissue concentrations of TR and bortezomib increased up to about threefold from the first to the third dose administration, after which they remained constant.
CONCLUSION: No undue tissue accumulation of TR and of bortezomib was observed in rats following a full clinical dosing cycle of bortezomib.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17285316     DOI: 10.1007/s00280-007-0424-9

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

Review 1.  Bortezomib for the treatment of non-Hodgkin's lymphoma.

Authors:  Prithviraj Bose; Michael S Batalo; Beata Holkova; Steven Grant
Journal:  Expert Opin Pharmacother       Date:  2014-09-29       Impact factor: 3.889

2.  Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice.

Authors:  Li Zhang; Donald E Mager
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-21       Impact factor: 2.745

Review 3.  Experimental approaches for the treatment of malignant gliomas.

Authors:  Leopold Arko; Igor Katsyv; Grace E Park; William Patrick Luan; John K Park
Journal:  Pharmacol Ther       Date:  2010-06-08       Impact factor: 12.310

4.  Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors.

Authors:  Toyoko Hiroi; Clayton B Deming; Haige Zhao; Baranda S Hansen; Elisabeth K Arkenbout; Thomas J Myers; Michael A McDevitt; Jeffrey J Rade
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-06       Impact factor: 8.311

5.  Cardiotoxicity of the anticancer therapeutic agent bortezomib.

Authors:  Dominika Nowis; Michał Maczewski; Urszula Mackiewicz; Marek Kujawa; Anna Ratajska; Mariusz R Wieckowski; Grzegorz M Wilczyński; Monika Malinowska; Jacek Bil; Pawel Salwa; Marek Bugajski; Cezary Wójcik; Maciej Siński; Piotr Abramczyk; Magdalena Winiarska; Anna Dabrowska-Iwanicka; Jerzy Duszyński; Marek Jakóbisiak; Jakub Golab
Journal:  Am J Pathol       Date:  2010-06       Impact factor: 4.307

6.  Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.

Authors:  Bret B Friday; S Keith Anderson; Jan Buckner; Chunrong Yu; Caterina Giannini; Francois Geoffroy; John Schwerkoske; Miroslaw Mazurczak; Howard Gross; Eduardo Pajon; Kurt Jaeckle; Evanthia Galanis
Journal:  Neuro Oncol       Date:  2011-11-16       Impact factor: 12.300

7.  A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drug-Drug Interactions of Bortezomib.

Authors:  Shinji Iwasaki; Andy Zhu; Michael Hanley; Karthik Venkatakrishnan; Cindy Xia
Journal:  AAPS J       Date:  2020-04-14       Impact factor: 4.009

8.  Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.

Authors:  Daniela A Bota; Daniela Alexandru; Stephen T Keir; Darell Bigner; James Vredenburgh; Henry S Friedman
Journal:  J Neurosurg       Date:  2013-10-04       Impact factor: 5.115

9.  Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.

Authors:  Deborah J Kuhn; Sally A Hunsucker; Qing Chen; Peter M Voorhees; Marian Orlowski; Robert Z Orlowski
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

10.  Bortezomib reverses a post-translational mechanism of tumorigenesis for patched1 haploinsufficiency in medulloblastoma.

Authors:  Eri Taniguchi; Min Jung Cho; Benjamin R Arenkiel; Mark S Hansen; Omar J Rivera; Amanda T McCleish; Stephen J Qualman; Denis C Guttridge; Matthew P Scott; Mario R Capecchi; Charles Keller
Journal:  Pediatr Blood Cancer       Date:  2009-08       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.